Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Laboratory Corporation of America Holdings    LH

News SummaryMost relevantAll newsSector newsTweets

Laboratory Corp. of America Holdings : LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

share with twitter share with LinkedIn share with facebook
share via e-mail
03/13/2012 | 10:05pm CET

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2012 to September 11, 2012, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 7, 2012, in addition to the continued accrual of the original issue discount. Contingent cash interest, which the Company has determined to be approximately $1.50 per Note, will be payable to holders of the Zero Coupon Notes as of the record date, which is August 26, 2012. The payment of contingent cash interest is expected to be made on September 11, 2012.

About LabCorp®

Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.5 billion in 2011, over 31,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technology through its specialized labs and the LabCorp Specialty Testing Group: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing, Litholink Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems, Inc., Monogram Biosciences, Inc., Colorado Coagulation, and Endocrine Sciences. LabCorp conducts clinical trials testing through its Esoterix Clinical Trials Services. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at: www.labcorp.com.

This press release contains forward-looking statements. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2011, and subsequent SEC filings.

Stephen Anderson, 336-436-5274

© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
01/19 LABORATORY CORP OF AMERICA HOLDINGS : Regulation FD Disclosure (form 8-K)
01/19 LABORATORY OF AMERICA : LabCorp Named to FORTUNE Magazine's 2018 List of ‘..
01/11 LABORATORY OF AMERICA : LabCorp is Scheduled to Present at the 36th Annual J.P. ..
01/11 LABORATORY OF AMERICA : Conversion Right Triggered For LabCorp's Zero Coupon Con..
01/11 LABORATORY OF AMERICA : LabCorp - Covance Introduces Dedicated Offering Designed..
01/11 LABORATORY OF AMERICA : New offering applies Chiltern-developed engagement model..
01/08 LABORATORY CORP OF AMERICA HOLDINGS : Regulation FD Disclosure (form 8-K)
01/08 LABORATORY OF AMERICA : Covance Introduces Dedicated Offering Designed for Biote..
01/08 LABORATORY OF AMERICA : LabCorp patents autism diagnosis method
01/04 LABORATORY OF AMERICA : Conversion Right Triggered For LabCorp's Zero Coupon Con..
More news
News from SeekingAlpha
01/09 Laboratory Corporation of America (LH) Presents At 36th Annual J.P. Morgan He..
01/05 More premarket analyst action - healthcare
2017 Tracking Larry Robbins' Glenview Capital Management Portfolio - Q3 2017 Updat..
2017 Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q3 2017 Upda..
2017 Quest Diagnostics takes issue with new 2018 Medicare reimbursement schedule, ..
Financials ($)
Sales 2017 10 184 M
EBIT 2017 1 700 M
Net income 2017 779 M
Debt 2017 6 547 M
Yield 2017 -
P/E ratio 2017 23,62
P/E ratio 2018 20,03
EV / Sales 2017 2,40x
EV / Sales 2018 2,16x
Capitalization 17 863 M
Duration : Period :
Laboratory Corporation of  Technical Analysis Chart | LH | US50540R4092 | 4-Traders
Technical analysis trends LABORATORY CORPORATION OF
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 181 $
Spread / Average Target 3,7%
EPS Revisions
David P. King Chairman, President & Chief Executive Officer
Glenn A. Eisenberg Chief Financial Officer, Treasurer & Executive VP
Mark Elliott Brecher Chief Medical Officer & Senior Vice President
Lance V. Berberian Chief Information Officer & Senior Vice President
Marcia T. Eisenberg Chief Scientific Officer & Senior Vice President
Sector and Competitors